Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
BeOne Medicines Ltd. - American Depositary Shares
(NQ:
ONC
)
320.35
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about BeOne Medicines Ltd. - American Depositary Shares
< Previous
1
2
3
4
Next >
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA
January 06, 2026
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 23, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
Earnings Scheduled For November 6, 2025
↗
November 06, 2025
Via
Benzinga
Where BeOne Medicines Stands With Analysts
↗
October 08, 2025
Via
Benzinga
Analyst Expectations For BeOne Medicines's Future
↗
September 18, 2025
Via
Benzinga
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma
December 18, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
December 08, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines Announced Sonrotoclax In Combination With BRUKINSA Demonstrated Rapid MRD Negativity In Treatment-naive CLL, Regardless Of High-risk Features
↗
December 07, 2025
BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating...
Via
Benzinga
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies
December 07, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied
↗
November 26, 2025
Novo Nordisk stock jumped Wednesday on a lighter-than-feared discount for Ozempic and Wegovy under the IRA.
Via
Investor's Business Daily
Topics
Economy
Government
U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
November 26, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025
November 20, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans
↗
November 17, 2025
Zymeworks rises after Ziihera shows significant PFS and OS benefits in a Phase 3 trial, supporting plans for regulatory filings and guideline submissions.
Via
Benzinga
Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
November 17, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates
November 06, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines to Present at Upcoming Investor Conferences
October 28, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
Investor Exits $5.5 Million Perpetua Resources Stake Amid Stock's 150% Rally
↗
October 27, 2025
Investor Exits $5.5 Million Perpetua Resources Stake Amid Stock's 150% Rally
Via
The Motley Fool
Topics
Regulatory Compliance
BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6
October 22, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
What's Going On With Summit Therapeutics Stock On Monday?
↗
October 20, 2025
Summit Therapeutics shares Phase 3 data showing ivonescimab cut cancer progression risk by 40% and plans BLA submission in late 2025.
Via
Benzinga
BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025
October 20, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA
October 13, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order
↗
September 10, 2025
Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs.
Via
Investor's Business Daily
Topics
Government
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
September 10, 2025
Via
Benzinga
Wayfair, United Therapeutics, And Ciena Are Among The Top 10 Large-Cap Gainers Last Week (July 14-July 18): Are The Others In Your Portfolio?
↗
September 07, 2025
These ten large-cap stocks were top performers last week. Are they a part of your portfolio?
Via
Benzinga
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
↗
September 02, 2025
Via
Benzinga
Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket
↗
September 02, 2025
Via
Benzinga
BeOne Medicines Stock Gains Momentum With Early-Stage Trial Success For Pretreated Lymphoma Patients
↗
August 29, 2025
BeOne Medicines reported positive Phase 1/2 results for sonrotoclax in relapsed or refractory mantle cell lymphoma, with regulatory submissions underway and a Phase 3 trial in progress.
Via
Benzinga
Affirm Posts Better-Than-Expected Earnings, Joins Ambarella, IREN, Petco Health and Wellness And Other Big Stocks Moving Higher On Friday
↗
August 29, 2025
Via
Benzinga
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
August 29, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025
August 27, 2025
From
BeOne Medicines Ltd.
Via
Business Wire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
